Persistencia con estatinas en prevención primaria de enfermedad cardiovascular: resultados en una cohorte de trabajadores españoles

Malo, Sara; Aguilar-Palacio, Isabel; Feja, Cristina; Menditto, Enrica; Lallana, María Jesús; Andrade-Gómez, Elena; Casasnovas, José A.; Rabanaque, María José

doi:10.1016/j.recesp.2017.03.027

Cited by 10 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is necessary to develop new strategies to disseminate the guidelines, and to emphasize the differences in intensity between statins and the importance of reaching target LDL-C levels to prevent CVD [26], particularly in the context of the poor control of hypercholesterolemia and other CVD risk factors in the Spanish population [27,28]. It should also be noted that the intensity of the prescribed statin influences treatment persistence [29], and that higher-intensity statins such as simvastatin, atorvastatin, and rosuvastatin have been associated with greater diabetogenic effects [30]. Further research will be needed to help identify other as-yet-unknown factors that may influence the choice of statin intensity, such as availability, price, and industry pressure.…”

Section: Discussionmentioning

confidence: 99%

Factors Associated with the Prescribing of High-Intensity Statins

Chaure-Pardos

Malo

Rabanaque

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

In this study, we investigated the relationship between sociodemographic, clinical, anthropometric, and lifestyle characteristics and the type of statin prescribed for primary prevention of cardiovascular disease (CVD). We conducted an observational study in workers who began statin treatment. Statin therapy was categorized as “high-intensity” or “low–moderate-intensity”. Workers were classified according to the alignment of their statin therapy with the recommended management practices. Logistic regression models were used to evaluate the association between the different variables studied and the probability of being prescribed high-intensity statins. The only variables associated with a higher probability of being treated with high-intensity statins were increased physical activity (>40 versus <20 METs (metabolic equivalent of task) h/wk; odds ratio (OR), 1.65; 95%CI, 1.08–2.50) and, in diabetics, higher low-density lipoprotein cholesterol (LDL-C) levels (≥155 mg/dL versus <155 mg/dL; OR, 4.96; 95%CI, 1.29–19.10). The model that best predicted treatment intensity included LDL-C, diabetes, hypertension, smoking, and age (area under the Receiver Operating Characteristic curve (AUC), 0.620; 95%CI, 0.574–0.666). The prescribing and type of statin used in primary CVD prevention did not correspond with the indications in current guidelines. The probability of receiving high-intensity statins was higher in diabetics with high LDL-C levels and in more physically active individuals. These findings underscore the great variability and uncertainty in the prescribing of statins.

show abstract